-

Elegen Launches New Online Ordering Portal for Rapid, High-Accuracy, Long DNA

Company focuses on ease of use, utility, and speed to increase ENFINIA DNA’s impact on workflow efficiency and productivity.

SAN CARLOS, Calif.--(BUSINESS WIRE)--Elegen, a global leader in DNA innovation, today announced the launch of a new online ordering portal. Available now from their website, the new portal streamlines the ordering process, empowering customers to easily place orders, and apply promotional discounts – all while keeping track of shipments and ordering history. With this exciting new development, Elegen reaffirms its commitment to delivering unparalleled service and technology to customers.

“We are committed to providing our customers with products that meet and exceed their expectations,” said Marc Unger, Elegen’s Chief Scientific Officer. “Our goal is to make the ordering process seamless, transparent, and efficient. Our new portal enables customers to easily leverage the benefits of our fast, long, and highly accurate DNA.”

Since the commercial launch of ENFINIA DNA in March, sales have ramped up quickly, enabling more customers to leverage Elegen’s cutting-edge technology to streamline workflows, reduce costs, and accelerate project timelines. Customers can order ENFINIA DNA up to 7,000 base pairs in length, with delivery in just 7 business days and an exceptional customer-validated per-base accuracy of approximately 99.999%. This industry-leading combination of speed, accuracy, and length provides customers with the benefits of clonal gene synthesis at a pace that rivals that of conventional gene fragments.

“ENFINIA DNA has changed the way our customers work, and the feedback we have received has been overwhelmingly positive,” said Matt Hill, Elegen’s Founder and CEO. “With ENFINIA DNA, customers are achieving remarkable results, from producing mRNA without cloning steps to assembling 40kb multi-trait cassettes for seed engineering with ease. Our customers are accomplishing more in less time and with less effort, leading to unprecedented productivity gains.”

Access Elegen’s new ordering portal by visiting ecommerce.elegen.com.

About Elegen

Elegen is bringing unique insights and technical innovation to create high-quality synthetic DNA faster, catalyzing the next revolution in the life sciences. The company is led by seasoned leaders with decades of experience in developing novel and scalable approaches in molecular biology, chemistry, and microfluidics. Elegen uses a proprietary microfluidics approach to build longer, higher-quality DNA on a faster timeline for agricultural, chemical, healthcare, and pharma industries. Founded in 2017, Elegen is privately held and based in the San Francisco Bay Area. For more information, visit elegenbio.com.

Contacts

ELEGEN CONTACT
Randy Dyer
Vice President, Marketing
Randy.dyer@elegenbio.com
650-787-0408

MEDIA RELATIONS
Tim Ingersoll
Tim@bioscribe.com

Elegen


Release Summary
Elegen Launches New Online Ordering Portal for Rapid, High-Accuracy, Long DNA
Release Versions

Contacts

ELEGEN CONTACT
Randy Dyer
Vice President, Marketing
Randy.dyer@elegenbio.com
650-787-0408

MEDIA RELATIONS
Tim Ingersoll
Tim@bioscribe.com

Social Media Profiles
More News From Elegen

Elegen Early Access Partners Receive High-Complexity, Long DNA Sequences in Rapid Time

SAN CARLOS, Calif.--(BUSINESS WIRE)--Elegen Early Access Partners Receive High-Complexity, Long DNA Sequences in Rapid Time at Lengths of 15,000 Base Pairs and Higher...

Elegen Launches ENFINIA™ DNA, Rapid Long DNA Synthesis to Power the Bioeconomy

SAN CARLOS, Calif.--(BUSINESS WIRE)--Elegen, a leader in DNA innovation, today announced that it has successfully concluded its early access program and is now offering global commercial access to its new class of double-stranded DNA, developed to power the synthetic biology revolution. Elegen’s ENFINIA™ DNA represents a major advance in the field, offering an unprecedented combination of length, speed, and accuracy to streamline synthetic biology workflows and scale to meet the demands of the...
Back to Newsroom